Orforglipron Constipation: Why It Happens and How to Manage It

Constipation is one of the most commonly reported side effects of orforglipron (Foundayo), showing up in roughly a fifth to a quarter of people in FDA trial data. It’s a known effect of the GLP-1 receptor agonist class, not a sign of a defective dose or a rare reaction, and for most people it’s manageable with everyday habits. Here’s why it happens, how common it actually is, and what’s worth doing about it — without inventing a fix this article can’t verify.

Why does orforglipron cause constipation?

Orforglipron is a GLP-1 receptor agonist — the same drug class as injectable semaglutide (Ozempic, Wegovy), oral semaglutide (Rybelsus), and tirzepatide (Mounjaro, Zepbound). Per MedlinePlus drug information on these medications, GLP-1 receptor agonists work partly by slowing gastric emptying and intestinal transit — food and waste move through the digestive tract more slowly. That slowdown is part of what makes GLP-1s effective for appetite regulation and weight management, and it’s also the mechanism behind constipation: less movement through the gut, especially at a new, higher dose, commonly means less regular bowel movements.

This isn’t unique to orforglipron. Constipation is a commonly reported effect across the GLP-1 and GLP-1/GIP class as a whole, whether the drug is a daily pill or a weekly injection, per the FDA-approved FOUNDAYO label and MedlinePlus information on semaglutide and tirzepatide. If you want the fuller side-effect picture beyond constipation specifically, our orforglipron side effects guide breaks down the full set of GI effects reported in FDA trial data.

How common is constipation on orforglipron?

Per FDA trial data cited in FOUNDAYO’s approved labeling, constipation was reported in roughly 20–27% of people across the approved maintenance doses, compared with about 9% on placebo. That makes it one of the more common GI effects alongside nausea, diarrhea, and vomiting — the full breakdown of all four is in our orforglipron side effects guide.

This is a trial-population range, not a prediction for any individual — plenty of people have a much easier time than the average suggests. Rates tend to be highest around a dose increase and lower once the body adjusts to a stable dose.

When does constipation typically show up?

Orforglipron follows a titration schedule: a low starting dose that increases roughly every 30 days, per the FDA label, up to a maximum maintenance dose. GI effects, including constipation, tend to cluster around those increases — more noticeable in the days to weeks after stepping up, then easing as the body adjusts before the next step. How to Take Orforglipron walks through the full titration schedule if you want to see where a rough patch might fall relative to your next dose increase.

That pattern matters because a stretch of irregularity after a dose increase isn’t automatically a bigger problem — it’s a known part of how the drug is introduced. What matters more is whether it settles at the new dose or keeps getting worse.

What helps with constipation on orforglipron?

None of this is medical advice — your prescriber and pharmacist are the right people to tailor guidance to your situation — but these are the commonly discussed, low-risk habits people use for GLP-1-related constipation:

• Increase water intake. Adequate fluids are a basic, low-risk step that supports regular bowel movements, especially as intestinal transit slows.
• Add fiber gradually, rather than all at once — a sudden jump in fiber can make bloating and discomfort worse before it helps.
• Stay physically active. Regular movement, even light walking, is commonly discussed as supportive of bowel regularity.
• Keep a consistent bathroom routine rather than ignoring the urge when it comes, which can make constipation worse over time.
• Don’t assume an over-the-counter laxative or stool softener is automatically safe to add — ask your pharmacist or prescriber first, especially if you take other medications or have other health conditions.

If eating patterns are the harder part of the picture — what and when to eat, not just bowel habits — Eating on Orforglipron covers meal patterns that tend to sit more comfortably during titration. And if nausea is the more prominent symptom for you, Managing Orforglipron Nausea covers the same “what helps, when to call” approach for that side effect specifically.

When should you talk to your prescriber?

Mild to moderate constipation, especially clustered around a dose increase, is expected and usually not a sign anything is wrong. But it’s worth knowing when to move from home management to a call. Contact your prescriber if:

• Constipation is severe, or doesn’t ease after several weeks at a stable dose.
• It comes with severe or persistent abdominal pain, significant bloating, or an inability to pass stool or gas — symptoms worth prompt evaluation rather than waiting out.
• You’re relying on laxatives regularly just to have a bowel movement, which is worth flagging even if each individual episode feels manageable.

None of this is meant to alarm you — for most people, GLP-1-related constipation is exactly what it looks like: a temporary adjustment that responds to basic habits. But severe or unusual symptoms are always worth a call rather than a guess.

Bottom line

Constipation on orforglipron is common, mechanism-driven — a byproduct of the slowed gastric and intestinal transit that’s part of how GLP-1 medications work — and for most people, manageable with hydration, gradual fiber, and movement. It tends to cluster around dose increases and ease as the body adjusts to each new level. Severe, persistent constipation, or constipation with significant abdominal pain or bloating, is the signal to call your prescriber rather than wait it out.

For the fuller picture of orforglipron’s side-effect profile and dosing schedule, see Foundayo (Orforglipron): A Simple Guide.